Biotech firm ImmunoPrecise's FY25 revenue misses estimates

Mindwalk Holdings

29/07/2025 13:39

Overview

ImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectations

Record Q4 revenue of C$7.0 mln, driven by BioStrand segment growth

Q4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiency

Outlook

Company anticipates completing divestiture of Dutch subsidiary soon

ImmunoPrecise to focus on AI-based product development

Company expects strategic steps to enhance core capabilities

ImmunoPrecise aims to streamline operations with strategic priorities

Result Drivers

BIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross margins

OPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiency

GROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenues

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
C$24.50 mln
C$25.40 mln (2 Analysts)
FY Net Income
-C$30.20 mln
FY Gross Profit
C$13.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.00, about 49.5% above its July 28 closing price of $2.02

Press Release: ID:nBw4tGpmKa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)